European Primary Care Cardiovascular Society

Primary Cardiovascular Care in Turkey (Turkish)

5' education - Dec. 10, 2018 - EPCCS Council Berlin - Dr. Zehra Dagli

Primary Cardiovascular Care in Ireland (English)

5' education - Dec. 10, 2018 - EPCCS Council Berlin - Dr. Cormac Ó Dubhghaill

Primary Cardiovascular Care in Germany (German)

5' education - Dec. 7, 2018 - EPCCS Council Berlin - Dr. Jan Oltrogge

Primary Cardiovascular Care in Germany (English)

5' education - Dec. 7, 2018 - EPCCS Council Berlin - Dr. Jan Oltrogge

Primary Cardiovascular Care in Slovakia (Slovak)

5' education - Dec. 5, 2018 - EPCCS Council Berlin - Michaela Macháčová, MD

Primary Cardiovascular Care in Slovakia (English)

5' education - Dec. 5, 2018 - EPCCS Council Berlin - Michaela Macháčová, MD

Primary Cardiovascular Care in Poland (Polish)

5' education - Dec. 5, 2018 - EPCCS Council Berlin - Pawel Żuk

Primary Cardiovascular Care in Poland (English)

5' education - Dec. 5, 2018 - EPCCS Council Berlin - Pawel Żuk

Primary Cardiovascular Care in Belgium (Flemish)

5' education - Dec. 5, 2018 - EPCCS Council Berlin - Bert Vaes, MD, PhD

Primary Cardiovascular Care in Belgium (English)

5' education - Dec. 5, 2018 - EPCCS Council Berlin - Bert Vaes, MD, PhD

Primary Cardiovascular Care in Montenegro (English)

5' education - Dec. 4, 2018 - EPCCS Council Berlin - Assist. Prof. dr. Milena Cojić

Primary Cardiovascular Care in Serbia (Serbian)

5' education - Dec. 4, 2018 - EPCCS Council Berlin - Dr Mira Kis-Veljkovic

Primary Cardiovascular Care in Ukraine (Ukrainian)

5' education - Dec. 4, 2018 - EPCCS Council Berlin - Maryna Dolzhenko

Primary Cardiovascular Care in Ukraine (English)

5' education - Dec. 4, 2018 - EPCCS Council Berlin - Maryna Dolzhenko

Primary Cardiovascular Care in Czech Republic (Czech)

5' education - Dec. 4, 2018 - EPCCS Council Berlin - Norbert Král

Primary Cardiovascular Care in Czech Republic (English)

5' education - Dec. 4, 2018 - EPCCS Council Berlin - Norbert Král

Primary Cardiovascular Care in Serbia (English)

5' education - Dec. 3, 2018 - EPCCS Council Berlin - Dr Mira Kis-Veljkovic - EPCCS Council 2018

Vitamin D and omega-3 did not achieve primary cancer and CV endpoints in primary prevention cohort

3' education - Nov. 26, 2018 - JoAnn Manson, MD - Boston, MA, US

In physical activity every step counts for everybody

3' education - Nov. 26, 2018 - Admiral Brett Giroir, MD - Washington, DC, USA

Different compounds of fish oils have different effects

3' education - Nov. 26, 2018 - Deepak Bhatt, MD - Boston, MA, VS.

Elevated BP before the age of 40 years affects the risk of incident CVD events in middle age

Literature - Dec. 10, 2018 - Yano Y et al., - JAMA. 2018

Community-based data show that increasing categories of severity of hypertension according to the 2017 ACC/AHA BP Guidelines are associated with increasing risk of CVD events in middle age.

DOAC treatment also found safe and effective in AF patients with multi-morbidity

Literature - Dec. 5, 2018 - Alexander KP et al. - American Heart Journal 2018

A post-hoc analysis of the ARISTOTLE trial showed safety and efficacy of apixaban compared to warfarin in AF patients aged 55 years or older with multi-morbidity.

Western lifestyle rather than natural course seems to underlie age-associated BP rise

Literature - Dec. 3, 2018 - Mueller NT et al. - JAMA Cardiol. 2018

A small cross-sectional study showed an age-associated rise in BP starting in childhood in a more Westernized community, compared to an isolated, non-acculturated community.

Vitamin D and omega-3 did not achieve primary cancer and CV endpoints in primary prevention cohort

AHA 2018 - Chicago, IL, US

3' education - Nov. 26, 2018 - JoAnn Manson, MD - Boston, MA, US
VITAL evaluated both vitamin D and omega-3 supplementation and did not find effect on the primary cancer and CV endpoints. Secondary endpoints suggest lower total MI with omega-3 suplementation.

AHA 2018 VITAL evaluated both vitamin D and omega-3 supplementation and did not find effect on the primary cancer and CV endpoints. Secondary endpoints suggest lower total MI with omega-3 suplementation.

In physical activity every step counts for everybody

AHA 2018 - Chicago, IL, USA

3' education - Nov. 26, 2018 - Admiral Brett Giroir, MD - Washington, DC, USA
Adm. Giroir emphasizes the importance for anyone of being physically active, and how recommended levels can easily be achieved. This is important for individual health, but also for national security.

AHA 2018 Adm. Giroir emphasizes the importance for anyone of being physically active, and how recommended levels can easily be achieved. This is important for individual health, but also for national security.

Different compounds of fish oils have different effects

AHA 2018 – Chicago, IL, USA

3' education - Nov. 26, 2018 - Deepak Bhatt, MD - Boston, MA, VS.
Deepak Bhatt considers the compounds that were tested in the VITAL and REDUCE-IT trials, which yielded neutral and very positive results, respectively, and what likely caused this discrepancy.

AHA 2018 Deepak Bhatt considers the compounds that were tested in the VITAL and REDUCE-IT trials, which yielded neutral and very positive results, respectively, and what likely caused this discrepancy.

Stimulating physical health with comprehensive US approach should tackle obesity and improve health

AHA 2018 - Chicago, IL, USA

3' education - Nov. 26, 2018 - Dr. Ivor Benjamin - Milwaukee, WS, USA
U.S. Department of Health & Human Services and AHA teamed up to engage entire communities to be more physically active, by highlighting the evidence that shows that health will benefit from it.

AHA 2018 U.S. Department of Health & Human Services and AHA teamed up to engage entire communities to be more physically active, by highlighting the evidence that shows that health will benefit from it.

Consideration of SGLT2 inhibitor treatment in broader T2DM population

AHA 2018 - Chicago, IL, VS

3' education - Nov. 26, 2018 - Steve Wiviott, MD - Boston, MA, VS.
Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.

AHA 2018 Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.

Interesting insights on CV-relevant inflammatory pathway with methotrexate in neutral study

AHA 2018 - Chicago, IL, USA

3' education - Nov. 26, 2018 - Paul Ridker, MD - Boston, MA, VS
Paul Ridker outlines how the new CIRT results add to our understanding of inflammation biology in relation to CV risk and how this directs future studies of inflammation.

AHA 2018 Paul Ridker outlines how the new CIRT results add to our understanding of inflammation biology in relation to CV risk and how this directs future studies of inflammation.

Discovering of more structural brain abnormalities in prediabetes compared to no diabetes

Literature - Nov. 22, 2018 - Van Agtmaal MJM et al. - Diab Care 2018

Structural brain abnormalities are more common in patients with prediabetes compared with non-diabetics, and even more common in T2DM patients.

Improved quality of life with yoga-based cardiac rehabilitation

AHA 2018 - Chicago, IL, USA

3' education - Nov. 22, 2018 - Dorairaj Prabhakaran, MD - New Delhi, India
Dorairaj Prabhakaran showed improved quality of life and return to pre-infarct daily activities with the Yoga-CaRe program as replacement for cardiac rehabilitation in post-MI patients.

AHA 2018 Dorairaj Prabhakaran showed improved quality of life and return to pre-infarct daily activities with the Yoga-CaRe program as replacement for cardiac rehabilitation in post-MI patients.

Lower HF hospitalization with SGLT2 inhibitor in both primary and secondary prevention T2DM patients

AHA 2018 – Chicago, IL, USA

News - Nov. 22, 2018

AHA 2018 Dapagliflozin was associated with a reduction in CVD/hospitalization in T2DM patients with ASCVD or with multiple risk factors, and with a modest decrease in MACE in those with existing ASCVD.